Conditions: Solid Tumors
Keywords: Solid Tumors MSC2156119J c-Met inhibitor Japanese Phase 1
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 12
Healthy volunteers: no

Brief summary:
This is a Japanese multicenter, open-label, Phase 1 study to evaluate safety and efficacy of MSC2156119J in subjects with malignant solid tumor which is refractory to standard therapy or to which no effective standard therapy is applicable.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: MSC2156119J
Intervention descriptions: intervention 1: Subjects will be administered with MSC2156119J 215 mg, 300 mg and 500 mg orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity.

Protocol document: